Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
MarketBeat

LENZ Therapeutics Q1 Earnings Call Highlights

LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and routine prescribing by eye care professionals are developing more gradually than expected.

President and Chief Executive Officer Eef Schimmelpennink said the company delivered approximately 25,000 paid and filled prescriptions in the quarter, bringing total monthly units sold since launch to roughly 46,000. LENZ generated $1.9 million in net revenue, including $1.7 million in product sales.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.